Newomics Inc., a Berkeley, Calif.-based biotechnology company developing and commercializing mass spectrometry solutions for molecular detection applications, closed a $7.9m Series B financing.
The round was led by MSA Capital with participation from new investor LDV Partners, and existing Series A investors the Berkeley Catalyst Fund and the Photon Fund.
The proceeds will be used to launch new products, grow the sales and marketing team, enhance customer support, and expand the collaborations with prominent mass spectrometer vendors.
Led by Daojing Wang, Ph.D., founder and CEO, and co-founder Pan Mao, Newomics is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s products deliver microflow LC and nanospray ionization MS. The plug-and-play MnESI platform (MnESI source + M3 emitter) is currently interfaced to diverse MS instruments.
Towards those goals, Newomics recently announced a new product MnESI-MS platform for clinical diagnostics and drug discovery research, completed the second co-marketing agreement with Thermo Fisher Scientific, and filled several positions in sales and marketing.